# US 2012/0252719 A1 · Water soluble membrane proteins and methods for the preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252719 A1
- Document ID: US20120252719A1
- Status: Published application
- Kind: A1
- Application number: 13/403,725
- Filed: 2012-02-23
- Published: 2012-10-04
- Earliest claimed: 2011-02-23
- Assignees: Massachusetts Institute of Technology
- Inventors: Shuguang Zhang; Alexander Rich; Karolina Corin; Lotta T. Tegler
- Web page: https://patentgrep.com/patent/US20120252719A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/7158: {for chemokines}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof.

## Claims

### Claim 1

A water-soluble polypeptide comprising a modified a-helical domain, wherein the modified α-helical domain comprises an amino acid sequence in which one or more hydrophobic amino acid residues within a α-helical domain of a native membrane protein is replaced with one or more hydrophilic amino acid residues.

### Claim 2 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the α-helical domain is 7-transmembrane α-helical domain.

### Claim 3 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the native membrane protein is a G-protein coupled receptor (GPCR).

### Claim 4 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the native membrane protein is an integral membrane protein.

### Claim 5 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the hydrophilic residues are selected from the group consisting of glutamine (Q), threonine (T), tyrosine (Y) and any combination thereof.

### Claim 6 (depends on 1)

The water-soluble polypeptide of claim 1, wherein one or more of the hydrophobic residues leucine (L), isoleucine (I), valine (V) and phenylalanine (F) are replaced.

### Claim 7 (depends on 1)

The water-soluble polypeptide of claim 1, wherein one or more phenylalanine residues of the α-helical domain of the native membrane protein are replaced with tyrosine, wherein one or more isoleucine and/or valine residues of the a-helical domain of the protein are replaced with threonine, or wherein wherein one or more leucine residues of the a-helical domain of the native membrane protein are replaced with glutamine.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the native membrane protein is an olfactory receptor or chemokine receptor CXCR4.

### Claim 11 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the native membrane protein is a mammalian protein.

### Claim 12 (depends on 10)

The water-soluble polypeptide of claim 10, wherein the native membrane protein is mOR103-15 or or chemokine receptor CXCR4.

### Claim 13 (depends on 12)

The water-soluble polypeptide of claim 12, wherein the hydrophobic amino acid residues at a-helical positions b, c and f are replaced.

### Claim 14 (depends on 12)

The water-soluble polypeptide of claim 12, wherein the hydrophobic amino acid residues at a-helical positions a, d, e and g are not replaced.

### Claim 15 (depends on 1)

The water-soluble polypeptide of claim 1, comprising the amino acid sequence of MERRNHTGRV SEFVLLGFPA PAPQRALQFF QSLQAYVQTL TENIQTITAIRNHPTLHKPM YYFLANMSFYL ETWYTTVTTP KMQAGYIGSE ENHGQLISFE ACMTQLYFFQ GLGCTECTLL AVMAYDRYVA TCHPLHYPVI VSSRQCVQMA AGSWAGGFGT SMTVKVYQISR LSYCGPNTIN HFFCDVSPLL NLSCTDMSTA ELTDFILAIF ILLGPLSVTG ASYMAITGAV MRIPSAAGRH KAFSTCASHL TTVITYYAAS IYTYARPKAL SAFDTNKLVS VLYAVIVPLL NPIIYCLRNQ EVKKALRRTL HLAQGDANT KKSSRDGGSS GTETSQVAPA (SEQ ID NO: 2); or MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANYNKTFLPTIYSIIY QTGI VGNGLVILVMGYQKKLRSMTDKYRLHLSTADLQFVTTLPYWADATANWY FGNFLCKAVHVIYTVNLYS SVLILAFISLDRYLAIVHATNSQRPRKLLAEKVV YVGVWTPAQLLTTPDYTFANVSEADDRYICDRFYPNDLWVVVFQFQHIMVG LILPGIVILSCYCIIISKLSHSKGHQKRKALKTTTLIQAFFACWQPYYTGISIDS YILLEIIKQGCEFENTVHKWISTTEAQAFYHCCTNPTQYAYLGAKFKTSAQHA LTSVSRGSSLKILSKGKRGGHSSVSTESESSSSFHS (SEQ ID NO:10).

### Claim 16 (depends on 2)

The water-soluble polypeptide of claim 2, wherein the modified 7-transmembrane α-helical domain comprises one or more of the following amino acid sequences:
(SEQ ID NO: 3)
a.
PQRALQFFQSLQAYVQTLTENIQTITAI R
(SEQ ID NO: 4)
b.
M YYFLANMSFYLETWYTTVTTPKMQAGYI
(SEQ ID NO: 5)
c.
CMTQLYFFQGLGCTECTLLAVMAYDRYVA TC
(SEQ ID NO: 6)
d.
RQCVQMAAGSWAGGFGTSMTVKVYQ
(SEQ ID NO: 7)
e.
LTDFILAIFILLGPLSVTGASYMAITGAV
(SEQ ID NO: 8)
f.
HKAFSTCASHLTTVITYYAAS IYTY
(SEQ ID NO: 9)
g.
TNKLVSVLYAVIVPLLNPIIYCLRN.

### Claim 17 (depends on 1)

The water-soluble polypeptide of claim 1, wherein the polypeptide retains the biological activity of the native membrane protein.

### Claim 18 (depends on 1)

The water-soluble polypeptide of claim 1, wherein one or more amino acids within potential odorant binding sites are not replaced.

### Claim 19

A method of preparing a water-soluble polypeptide comprising replacing one or more hydrophobic amino acid residues within the α-helical domain of a native membrane protein with one or more hydrophilic amino acid residues.

### Claim 20 (depends on 19)

The method of claim 19, wherein the α-helical domain is a 7-transmembrane α-helical domain.

### Claim 21 (depends on 19)

The method of claim 19, wherein the native membrane protein is a G-protein coupled receptor (GPCR).

### Claim 22 (depends on 19)

The method of claim 19, wherein the hydrophilic residues are selected from the group consisting of glutamine (Q), threonine (T), tyrosine (Y) and any combination thereof.

### Claim 23 (depends on 19)

The method of claim 19, wherein the hydrophobic residues leucine (L), isoleucine (I), valine (V) and phenylalanine (F) are replaced.

### Claim 24 (depends on 20)

The method of claim 20, wherein one or more phenylalanine residues of the 7-transmembrane α-helical domain of the native membrane protein are replaced with tyrosine, wherein one or more isoleucine and/or valine residues of the α-helical domain of the native membrane protein are replaced with threonine, or wherein one or more leucine residues of the α-helical domain of the native membrane protein are replaced with glutamine.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 19)

The method of claim 19, wherein the water-soluble polypeptide retains the biological activity of the native membrane protein.

### Claim 33 (depends on 19)

The method of claim 19, further comprising determining the secondary structure of the polypeptide or measuring ligand binding.

### Claim 34 (depends on 33)

The method of claim 33, wherein the secondary structure is determined using circular dichroism.

### Claim 35

(canceled)

### Claim 36 (depends on 19)

The method of claim 19, wherein the polypeptide is prepared using a cell-free system.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41 (depends on 19)

A polypeptide produced according to the method of claim 19.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

A method for treating a mammal suffering from a disorder or disease that is mediated by the activity of a native membrane protein, comprising administering to said mammal an effective amount of a water-soluble polypeptide comprising a modified α-helical domain, wherein the modified α-helical domain comprises an amino acid sequence in which one or more hydrophobic amino acid residues within a α-helical domain of the native membrane protein is replaced with one or more hydrophilic amino acid residues.

### Claim 46

(canceled)

### Claim 47

(cancelled)

### Claim 48

(cancelled)

### Claim 49 (depends on 45)

The method of claim 45, wherein the hydrophilic residues are selected from the group consisting of glutamine (Q), threonine (T), tyrosine (Y) and any combination thereof.

### Claim 50 (depends on 45)

The method of claim 45, wherein one or more of the hydrophobic residues leucine (L), isoleucine (I), valine (V) and phenylalanine (F) are replaced.

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 45)

The method of claim 45, wherein said native membrane protein is abnormally activated, up-regulated, or over-expressed in a disorder or disease.

### Claim 55 (depends on 45)

The method of claim 45, wherein the disease is cancer, Parkinson's disease, cardiovascular disease, hypertension or asthma.

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63 (depends on 45)

The method of claim 45, wherein the native membrane protein is selected from the group comprising purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6), M1 and M3 muscarinic acetylcholine receptors, receptors for thrombin [protease-activated receptor (PAR)-1, PAR-2], thromboxane (TXA2), sphingosine 1-phosphate (S1P2, S1P3, S1P4 and S1P5), lysophosphatidic acid (LPA1, LPA2, LPA3), angiotensin II (AT1), serotonin (5-HT2c and 5-HT4), somatostatin (sst5), endothelin (ETA and ETB), cholecystokinin (CCK1), V1a vasopressin receptors, D5 dopamine receptors, fMLP formyl peptide receptors, GAL2 galanin receptors, EP3 prostanoid receptors, A1 adenosine receptors, α1 adrenergic receptors, BB2 bombesin receptors, B2 bradykinin receptors, calcium-sensing receptors, chemokine receptors, KSHV-ORF74 chemokine receptors, NK1 tachykinin receptors, thyroid-stimulating hormone (TSH) receptors, protease-activated receptors, neuropeptide receptors, adenosine A2B receptors, P2Y purinoceptors, metabolic glutamate receptors, GRK5, GPCR-30, and CXCR4.

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

A method for producing a native ligand binding modified polypeptide of a transmembrane protein comprising the step of replacing or mutating at least some of the hydrophobic amino acid residues by hydrophilic amino acid residues wherein said modified polypeptide retains at least some of the ligand binding properties of said transmembrane protein.

### Claim 74

A method for treating a disease or disorder mediated by ligand binding of a transmembrane protein comprising the step of administering a modified polypeptide wherein said polypeptide corresponds to a mutated amino acid sequence of said protein wherein transmembrane region of the sequence is modified so that at least some of the hydrophobic amino acid residues are replaced by hydrophilic amino acid residues.

### Claim at position 75

75-89. (canceled)

### Claim 90 (depends on 1)

A pharmaceutical composition comprising an effective amount of a water-soluble polypeptide of claim 1, and a pharmaceutically acceptable diluent or carrier.
